Alex Hanan
As Told By The LCFA Board of Directors

Alex Hanan was in his early 40s; a non-smoking, healthy young man, who exercised regularly, ate relatively well and had a great group of truly dedicated friends.

In January of 2014, Alex was diagnosed with Stage 4 Lung Cancer.  It was a great shock to him, his family and his friends.

Alex was not who most people think of when they think of lung cancer.  But, people exactly like Alex are the new faces of this disease.

Although it seems like a poor choice of words, Alex was also lucky.   He was among those lung cancer patients who have been able to benefit from the fantastic strides in lung cancer research in recent years.

Alex’s doctors, after doing genetic testing, determined that he tested positive for the EGFR mutation and was eligible for the FDA approved targeted therapy drug, Tarceva. Only 1 in 7 patients are genetically eligible for this drug and only 60-70% of these patients see successful results. But, Alex was one of those lucky few.

As Alex’s lung cancer story continued to evolve, he continued to fight the disease every day.  But, Alex, in his own words, urged his friends and family not to worry about him and his lung cancer.  He always said, “I got this.”

And he did have it. He had it under control through 4+ years, through a major job change and a cross-country move.

Sadly, Alex left us all on Monday, July 23, 2018 but his story will always be remembered and his spirit lives on in us all.

Life should take your breath away, not lung cancer.

Sign up for the Lung Cancer Foundation of America’s newsletter to get more resources on lung cancer risks, symptoms and warning signs.

Get informed. Stay informed.